Nexus Pharmaceuticals Announces Launch of Erythromycin Lactobionate for Injection, USP

LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--Nexus Pharmaceuticals announced the launch of Erythromycin Lactobionate for Injection, USP in 500mg/vial in single-dose vials. It is an AP-rated generic to ERYTHROCIN™¥.

“The launch of Erythromycin Lactobionate showcases Nexus’ commitment to providing critical antibiotics where and when they are needed most,” said Vince LoPiccolo, Vice President of Sales and Marketing at Nexus Pharmaceuticals. “Erythromycin is the first of many upcoming antibiotics that Nexus will be providing in the near future as we continue to bolster domestic medication production.”

Nexus Pharmaceuticals’ Erythromycin Lactobionate for Injection is available in cartons of five single-dose vials.

About Erythromycin Lactobionate for Injection, USP

Erythromycin Lactobionate for Injection, USP is indicated in the treatment of infections caused by susceptible strains of designated organisms when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin.

For prescribing information, please see the following link.

About Nexus Pharmaceuticals

Nexus Pharmaceuticals, a US-based healthcare company and certified diverse supplier, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor-intensive, and more streamlined in practice. Nexus ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and delivers dependable life-saving treatment options when and where they’re needed most. For more information about Nexus Pharmaceuticals and its state-of-the-art Wisconsin manufacturing facility, visit www.nexuspharma.net/project-tomorrow/.

¥ERYTHROCIN™ is a registered trademark of Pfizer, Inc.